Enhanced Datamart
Our foundational data subscriptions, Enhanced Datamarts (EDMs), cover 22 tumor types and deliver a wide pool of clinical data sourced from electronic health records.
Accelerate oncology research with real-world evidence
Flatiron Enhanced Datamarts enable researchers to monitor and analyze key aspects of the patient journey. Sourced from the electronic health records of hundreds of thousands of patients in Flatiron’s OncoEMR, these curated, longitudinal, de-identified datasets contain a combination of structured and more sophisticated abstracted, derived, and extracted data elements for 22 different cancer types.
EDMs are refreshed monthly with 30-day recency, allowing you to understand treatment journeys from diagnosis onward.
Available data
22 disease-specific data models
EDMs for the following cancer types are currently available:
-
Acute myeloid leukemia
-
Early breast cancer
-
Metastatic breast cancer
-
Chronic lymphocytic leukemia
-
Metastatic colorectal cancer
-
Diffuse large B-Cell lymphoma
-
Advanced endometrial cancer
-
Follicular lymphoma
-
Advanced gastric/esophageal cancer
-
Advanced head and neck cancer
-
Hepatocellular carcinoma
-
Mantle cell lymphoma
-
Advanced melanoma
-
Multiple myeloma
-
Early non-small cell lung cancer
-
Advanced non-small cell lung cancer
-
Ovarian cancer
-
Metastatic pancreatic cancer
-
Metastatic prostate cancer
-
Metastatic renal cell carcinoma
-
Small cell lung cancer
-
Advanced urothelial carcinoma
Introducing
Flexible add-on variables
Gain greater flexibility and address more use cases, in less time
Quickly access additional variables for a larger pool of patients, seamlessly delivered alongside an existing data subscription. Choose from a menu of optional flexible add-ons, like outcome variables such as real-world response and progression.
Derive real-world endpoints with outcome variables
Real-world response
Now offered at scale, using cutting edge machine learning technology
Assessing real-world response in a broad population unlocks insights across the oncology drug development lifecycle
Real-world response captures the clinician’s assessment of change in disease burden following radiographic imaging. It is one of our most critical and frequently-requested variables, and is now available for an unprecedented number of patients.
Leveraging ML-data extraction models trained and validated on high-quality, clinically curated data, we offer real-world response data at the quality, scale, and speed needed to answer a wide range of research questions.
Real-world progression
Derive real-world progression-related endpoints, such as real-world progression free survival (rwPFS), for certain diseases.
Real-world mortality
Conduct robust survival analyses, such as real-world overall survival (rwOS) for studies with our validated mortality variable, available with all EDM subscriptions.
